Hepatitis C: Practical, Medical, and Spiritual Guidelines for Daily Living with HCV (Hazelden Pocket Health Guide)
CBC.ca (Free subscription) | 11/06/2009
Canadian taxpayers could be on the hook for millions of dollars in health care costs unless something is done to stop the spread of hepatitis C among injection drug users in federal prisons, a House of Commons committee heard.
Denver Christian Docs (Free subscription) | 11/05/2009
Just came across my Email that there is a new strain of Hepatitis C among gay men in New York City. As a pathologist I really dislike Hep C. It gets lab people all the time with needle sticks, etc. I'm a lot more afraid of Hep C than of HIV. And a new strain, efficiently sexually transmitted, with rapid liver damage?
SeekingAlpha.com (Free subscription) | 11/05/2009
Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...
Business Wire (Free subscription) | 11/05/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial results for the third quarter and nine months ended September 30, 2009. “We have continued development of our pipeline of drug candidates targeted to Toll-like receptors for potential applications in chronic hepatitis C virus infection and autoimmune diseases, and to support our partnered programs...
Medical News Today (Free subscription) | 11/04/2009
Tibotec announced results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours, in combination with standard of care.
Business Wire (Free subscription) | 11/04/2009
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA. TMC435 is an investigational protease inhibitor, being developed by Tibotec in collaboration with Medivir, for the treatment of hepatitis C virus (HCV). Data for TMC435 in...
Xconomy (Free subscription) | 11/04/2009
A number of New England’s life sciences companies had good news to report this week. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) reported results from clinical trials that indicate its experimental hepatitis C drug, telaprevir, could work well for patients who haven’t responded fully to standard treatments, and could be as effective taken twice a day as [...]
PR News Wire (Free subscription) | 11/03/2009
BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) and Pharmasset, Inc. (Nasdaq: VRUS) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus (HCV).(i) The study, conducted...
Business Wire (Free subscription) | 11/03/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9 (TLR9). Two presentations are being made today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, MA. “Induction of endogenous...
PR News Wire (Free subscription) | 11/03/2009
ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, were presented at the American Association for the Study of Liver...
PR News Wire (Free subscription) | 11/03/2009
CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today that it has initiated a Phase II clinical trial evaluating IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV, in combination with pegylated...
Medical News Today (Free subscription) | 11/03/2009
Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested.
Medical News Today (Free subscription) | 11/03/2009
All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected.
Medical News Today (Free subscription) | 11/03/2009
Schering-Plough Corporation (NYSE: SGP) reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
Xconomy (Free subscription) | 11/03/2009
Combination therapy has been a central component of treatment for certain viral diseases for more than 15 years. The benefits of combination therapy can arise from activation of multiple host pathways, suppression of mutational variants that can lead to viral escape, or perhaps both. In HIV, the benefit of combination therapy is due to suppression [...]
The 3 latest articles published by users on Hepatitis C :
saxondc3jj | 10/31/2009
Buy Rebetol without prescription - Click Here! >>> Rebetol is used for treatment of hepatitis C infection in certain patients when used in combination with interferon. Order Rebetol at one of the trusted online pharmacies and save your money. Check Prices and Buy Rebetol Important! Free Pills with EVERY order! No prescription is needed! Safe and Secured 100% Best Customer service Click Here to Order...
aarkstore | 10/29/2009
Hepatitis C Therapy Area Pipeline Report contains detailed information on the hepatitis c drug pipeline. This report provides insight into the pipeline status of hepatitis c drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage,...
aarkstore | 10/22/2009
The Hepatitis C Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments. Dosing information and treatment costs are provided for Peg-Intron, Pegasys, Rebetol, Copegus, and generic ribavirin capsules. General information on sales of peginterferon and ribavirin is provided. Additional Information Disease and Therapy...
Videos